Codexis receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Codexis Inc (CDXS)
Track today's live Codexis (CDXS) share price, performance and key data on this page with our current NASDAQ:CDXS stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Codexis share price on the NASDAQ exchange. Use the dropdown to switch exchange for the CDXS share price, head to our technical summary section, which provides analysis on Codexis share price buy/sell indicators using real-time data (or discuss the Codexis (CDXS) stock price today with other investors in the Codexis NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:CDXS share price (ISIN: US1920051067) to enhance your trading decisions with our free investment tools and resources.
What Is the Codexis Inc Share Price Today?
The Codexis share price today is 1.565.
What Is the Stock Symbol for Codexis Inc
The stock symbol (or 'ticker') for Codexis Inc is "CDXS."
What Stock Exchange Does Codexis Inc Trade On?
Codexis Inc is listed and trades on the NASDAQ stock exchange.
Is Codexis Inc a Good Stock to Buy?
Determining whether Codexis (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:CDXS share price (ISIN: US1920051067) to enhance your trading decisions with our free investment tools and resources.
What Is the Codexis Inc Share Price Today?
The Codexis share price today is 1.565.
What Is the Stock Symbol for Codexis Inc
The stock symbol (or 'ticker') for Codexis Inc is "CDXS."
What Stock Exchange Does Codexis Inc Trade On?
Codexis Inc is listed and trades on the NASDAQ stock exchange.
Is Codexis Inc a Good Stock to Buy?
Determining whether Codexis (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
1.565
+0.065(+4.33%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.520
1.575
52 wk Range
0.958
3.060
CDXS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.5201.575
52 wk Range
0.9583.060
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CDXS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
6.333
Upside
+304.69%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts do not anticipate the company will be profitable this year
Form 424B5 Codexis Inc For: 24 July- Investing.com
- Codexis receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
5 Buy
2 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 6.333
(+304.69% Upside)
Codexis Inc SWOT Analysis
Enzymatic Revolution | Codexis pivots to RNAi therapeutics manufacturing, leveraging its ECO Synthesis platform to address critical challenges in drug production scalability and efficiency |
Market Opportunity | Explore the billion-dollar potential in the growing RNAi therapeutics market, where Codexis aims to revolutionize manufacturing processes with its innovative approach |
Financial Fortitude | Delve into Codexis's robust financial position, with $90.3 million in cash reserves providing runway until 2027, despite current negative EBITDA of -$45.78 million |
Analyst Outlook | Cantor Fitzgerald maintains a consistent $11.00 price target throughout 2024, reflecting cautious optimism about Codexis's potential in the RNAi manufacturing arena |
Codexis Inc Earnings Call Summary for Q2/2026
- Codexis posted Q2 2026 revenue of $14.92M, beating estimates by 7.96%, with a 13-cent loss per share versus 14-cent forecast.
- Product gross margin improved to 73% as R&D and SG&A expenses fell 15.2% and 11.4% respectively; cash runway extended through 2028.
- Company maintained full-year 2026 revenue guidance of $72M-$76M with gross margin in high 60s, expecting back-half weighted results.
- ECO Synthesis platform showed progress with stereochemistry control and starterless RNA synthesis; GMP facility planned to scale production.
- One of three CDMO partners entered long-term commercial contract talks; management targets 500-gram scale by year-end, then kilogram scale.
Last Updated: 11/08/2026, 22:34
Read Full TranscriptEarnings
Latest Release
11/08/2026
EPS / Forecast
-0.13 / -0.14
Revenue / Forecast
14.92M / 13.82M
Compare CDXS to Peers and Sector
Metrics to compare | CDXS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCDXSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.3x | −1.6x | −0.3x | |
PEG Ratio | −0.09 | 0.00 | 0.00 | |
Price/Book | 5.0x | 4.9x | 2.6x | |
Price / LTM Sales | 2.1x | 7.1x | 3.1x | |
Upside (Analyst Target) | 333.3% | 54.0% | 50.4% | |
Fair Value Upside | Unlock | −2.8% | 6.4% | Unlock |
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Codexis (NASDAQ: CDXS) Share Price Today?
The Codexis stock price today is 1.565 USD.
What Stock Exchange Does Codexis (CDXS) Trade On?
Codexis is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Codexis?
The stock symbol (also called a 'ticker') for Codexis is "CDXS."
What Is the Current Codexis Market Capitalisation?
As of today, Codexis (NASDAQ: CDXS) market cap is 170.280M USD.
What Is Codexis's (CDXS) Earnings Per Share (TTM)?
The Codexis EPS is currently -0.339 (Trailing Twelve Months).
When Is the Next Codexis Earnings Date?
Codexis's next earnings report will be released on 29/10/2026.
Is CDXS a Buy or Sell From a Technical Analyst Perspective?
Based on today's Codexis moving averages and other technical indicators, the daily buy/sell signal for CDXS stock is Strong Sell.
How Many Times Has Codexis Stock Split?
Codexis has split 0 times. (See the CDXS stock split history page for full effective split date and price information.)
How Many Employees Does Codexis Have?
Codexis has 146 employees, based on their latest Companies House report.
What is the current trading status of Codexis (NASDAQ: CDXS)?
As of 19/08/2026, Codexis (CDXS) is trading at a share price of 1.565 USD, with a previous close of 1.500 USD. The stock has fluctuated within a day range of 1.520 USD to 1.575 USD, while its 52-week range spans from 0.958 USD to 3.060 USD.
What Is Codexis (CDXS) Price Target According to Analysts?
The average 12-month price target for Codexis is 6.333 USD, with a high estimate of 11 USD and a low estimate of 2 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +304.69% Upside potential.
What Is the CDXS Premarket Price?
CDXS's last pre-market stock price is 1.512 USD. The pre-market share volume is 8,700.000, and the stock has decreased by 0.012, or 0.800%.
What Is the CDXS After Hours Price?
CDXS's last after hours stock price is 1.510 USD, the stock has decreased by 0.010, or 0.670%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.